Editorial Policy

Biotech Strategy Blog provides commentary and insight on oncology & hematology new product development in the pharma and biotech industries.

The blog frequently reports on clinical data presented at medical and scientific meetings run by AACR, ASCO, ASH, EHA, AUA, EAU & ESMO/ECCO.

Occasionally covered are themes such as innovation, nanotechnology, regenerative medicine, strategic issues in the biotechnology industry and promising scientific research in therapeutic areas such as osteoporosis, respiratory medicine and Alzheimer’s disease.

All the content is editorially independent, no post is sponsored and no paid advertising is accepted. Blog posts reflect the opinion of the author and not those of any employer or company. Unsolicited guest posts are not accepted. 

Some content (“Premium Content”) requires payment of a fee to access. All posts from 2010 and 2011 are free and open access.

By accessing or using this website, you accept and agree to the Terms of Use. These should be really carefully as upon acceptance they form a contract that governs your use of this site and purchase of Premium Content. If you do not wish to accept the Terms of Use you should not access or use this website.

Editor & Oncology Lead Writer

 AboutFrom September 2013, Sally Church, PhD has become the Editor of Biotech Strategy Blog and lead writer for oncology related content.

Recognized as an industry expert (she has appeared on CNBC and been widely quoted in the media, including NPR), Sally is considered to be one of the Top 50 women on Twitter, where as @MaverickNY she is a frequent commentator on oncology drug development. Sally uses the author name “MaverickNY” to identify her posts on this blog.

Since 2006 Sally has written the widely acclaimed Pharma Strategy Blog which showcases her knowledge of cancer biology and new product development. As part of her “Making a Difference” series she regularly conducts interviews with oncology thought leaders.

Time cover on Glivec 28 May 2001 228x300 AboutWith over 20 years experience in the pharmaceutical industry in the UK & United States, Sally has held executive positions in sales, marketing and new product development, and has received numerous business achievement awards.

At Novartis Oncology she co-led the initial US launches of Gleevec® in CML and GIST. Through her company, Icarus Consultants, Sally helps pharma & biotech companies understand the oncology market, and focus on the right target and commercial opportunity for new products.

Sally’s qualifications includes a PhD from Kings College London, MBA from Rutgers, Master of Science in Human & Applied Physiology and undergraduate degree in Sports Science. She is a keen sportswomen who has played at national and county level in cricket and hockey in the UK. Sally has also undertaken executive education in finance at Harvard Business School.

Sally donates her spare time to charitable cancer causes and sits on the board of directors of a non-profit organization, GRACE (Global Resource for Advancing Cancer Education) which focuses primarily on lung cancer education.

Contributing Writer

S7300188 150x1501 AboutPieter Droppert (@3NT) writes about drug development in the biopharma industry, innovation and clinical data that captures his attention at medical meetings.

Pieter’s experience includes project management of multi-national drug development trials with leading CROs and work as a strategy consultant for a top-tier management consulting firm. He has over 20 years of pharmaceutical industry experience in the UK, US & Canada.

Amongst his many qualifications, Pieter is a graduate of the Sloan Fellows program at London Business School. He has a master of science degree in human and applied physiology from Kings College London and a JD from Rutgers School of Law in Newark, NJ.

Pieter is a member of the National Association of Science Writers (NASW) and an associate member of the Association of Health Care Journalists (AHCJ).

Guest Writers

Posts on this blog may also be authored by invited guest writers. Author attribution is given in each post.